Redx Pharma (REDX)

Sector:

Pharma and Biotech

18.20p
   
  • Change Today:
    -0.55p
  • 52 Week High: 36.00
  • 52 Week Low: 17.50
  • Currency: UK Pounds
  • Shares Issued: 388.99m
  • Volume: 45,520
  • Market Cap: £70.80m
  • RiskGrade: 278

Redx collaboration with MDC awarded Innovate UK funding

By Josh White

Date: Tuesday 19 Nov 2019

LONDON (ShareCast) - (Sharecast News) - Redx Pharma announced on Tuesday that Innovate UK has awarded biomedical catalyst funding to Redx and Medicines Discovery Catapult (MCD).
The AIM-traded company said the grant would fund the development and validation of a panel of translational biomarkers to assess novel therapeutics in idiopathic pulmonary fibrosis (IPF), which it described as a life-threatening fibrotic lung condition.

It said the collaboration combined its expertise in the development of novel small molecule precision medicines, including its 'Porcupine' (RXC006) and 'Rho-associated protein kinase 2' (ROCK2) inhibitors, together with MDC's expertise in biomarker strategies.

The collaboration was expected to enable the progression of anti-fibrotic therapies in an area of high unmet medical need worldwide.

Development of new therapies for the treatment of fibrotic diseases was currently hampered by the lack of translation between animal models and human disease, Redx explained.

In addition, robust biomarker strategies that could be used to stratify patients, predict treatment efficacy and show a meaningful anti-fibrotic response early in clinical development did not exist at present.

Thus, new biomarkers validated and developed through the project were expected to "greatly assist" the development of new therapies for IPF, and improve the likelihood of clinical success.

The company said the project, funded by Innovate UK, aimed to set up and validate a "comprehensive group" of fibrotic disease-associated genes and proteins with the potential to further develop into a sensitive biomarker panel for clinical use.

A multimodal approach would be undertaken by MDC to investigate novel biomarker signatures to characterise disease and treatment response.

Those biomarkers could be used to evaluate Redx's Porcupine (RXC006) and ROCK2 small molecule inhibitors in preclinical fibrosis models, and ultimately support future clinical development strategies for those programmes, which aimed to enter the clinic by 2021.

The total grant awarded to fund this project was £0.516m.

"We are excited to enter into this unique collaboration with Medicines Discovery Catapult and would like to thank Innovate UK for the validation of our teams' scientific capabilities with the biomedical catalyst funding award," said Redx chief scientific officer Dr Richard Armer.

"This will accelerate preclinical assessment and ensure a robust clinical development plan is in place for our Porcupine and ROCK2 inhibitors for fibrosis."

Dr Peter Simpson, chief scientific officer at Medicines Discovery Catapult, added that the partnership with Redx would allow the development of a robust portfolio of biomarkers for IPF, and the progression of anti-fibrotic therapies in a faster and better-informed way.

"This exciting collaboration will enable us to better address an important and unmet clinical need."

At 0844 GMT, shares in Redx Pharma were up 5.71% at 7.4p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Redx Pharma Market Data

Currency UK Pounds
Share Price 18.20p
Change Today -0.55p
% Change -2.93 %
52 Week High 36.00
52 Week Low 17.50
Volume 45,520
Shares Issued 388.99m
Market Cap £70.80m
RiskGrade 278

Redx Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.01% below the market average61.01% below the market average61.01% below the market average61.01% below the market average61.01% below the market average
88.89% below the sector average88.89% below the sector average88.89% below the sector average88.89% below the sector average88.89% below the sector average
Price Trend
72.69% below the market average72.69% below the market average72.69% below the market average72.69% below the market average72.69% below the market average
26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average
Income Not Available
Growth
28.23% below the market average28.23% below the market average28.23% below the market average28.23% below the market average28.23% below the market average
35.14% below the sector average35.14% below the sector average35.14% below the sector average35.14% below the sector average35.14% below the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Redx Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
13:03 3,000 @ 18.00p
09:50 10 @ 18.95p
09:49 10 @ 18.95p
08:26 22,500 @ 18.00p
08:16 10,000 @ 18.08p

Top of Page